Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 552.6
(3.05%)
INR 552.6
(3.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.9 Billion INR | 10.85% |
| 2022 | 805.46 Million INR | -8.15% |
| 2021 | 876.97 Million INR | 9.9% |
| 2020 | 798 Million INR | 36.79% |
| 2019 | 583.38 Million INR | -4.08% |
| 2018 | 608.2 Million INR | 28.24% |
| 2017 | 474.26 Million INR | 12.38% |
| 2016 | 422.02 Million INR | 16.33% |
| 2015 | 362.79 Million INR | 61.0% |
| 2014 | 225.33 Million INR | 25.29% |
| 2013 | 179.85 Million INR | 22.07% |
| 2012 | 147.33 Million INR | 22.42% |
| 2011 | 120.34 Million INR | 5.43% |
| 2010 | 114.15 Million INR | 5.82% |
| 2009 | 107.87 Million INR | 19.03% |
| 2008 | 90.62 Million INR | 4.32% |
| 2007 | 86.87 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 195.07 Million INR | 205.94% |
| 2023 Q4 | 156.97 Million INR | -41.53% |
| 2023 FY | 892.85 Million INR | 10.85% |
| 2023 Q1 | 181.72 Million INR | 0.26% |
| 2023 Q2 | 372.62 Million INR | 105.05% |
| 2023 Q3 | 268.47 Million INR | -27.95% |
| 2022 Q2 | 322 Million INR | 116.95% |
| 2022 Q3 | 308.46 Million INR | -4.2% |
| 2022 Q4 | 181.25 Million INR | -41.24% |
| 2022 Q1 | 148.42 Million INR | -5.78% |
| 2022 FY | 805.46 Million INR | -8.15% |
| 2021 Q4 | 157.52 Million INR | -25.94% |
| 2021 FY | 876.97 Million INR | 9.9% |
| 2021 Q1 | 233.96 Million INR | 74.53% |
| 2021 Q2 | 272.79 Million INR | 16.6% |
| 2021 Q3 | 212.69 Million INR | -22.03% |
| 2020 Q3 | 181.05 Million INR | -35.03% |
| 2020 Q2 | 278.69 Million INR | 37.36% |
| 2020 Q1 | 202.9 Million INR | 116.73% |
| 2020 Q4 | 134.05 Million INR | -25.96% |
| 2020 FY | 798 Million INR | 36.79% |
| 2019 Q3 | 113.08 Million INR | -50.64% |
| 2019 Q4 | 93.61 Million INR | -17.21% |
| 2019 FY | 583.38 Million INR | -4.08% |
| 2019 Q1 | 172.01 Million INR | 64.26% |
| 2019 Q2 | 229.09 Million INR | 33.19% |
| 2018 Q1 | 217.13 Million INR | 167.44% |
| 2018 Q4 | 104.72 Million INR | -10.27% |
| 2018 Q2 | 175.78 Million INR | -19.04% |
| 2018 Q3 | 116.7 Million INR | -33.61% |
| 2018 FY | 608.2 Million INR | 28.24% |
| 2017 Q3 | 175.89 Million INR | 5.86% |
| 2017 FY | 474.26 Million INR | 12.38% |
| 2017 Q4 | 81.18 Million INR | -53.84% |
| 2017 Q2 | 166.16 Million INR | 96.0% |
| 2017 Q1 | 84.77 Million INR | 137.27% |
| 2016 FY | 422.02 Million INR | 16.33% |
| 2016 Q3 | 103.33 Million INR | -22.08% |
| 2016 Q2 | 132.6 Million INR | -20.46% |
| 2016 Q1 | 166.71 Million INR | 62.85% |
| 2016 Q4 | 35.72 Million INR | -65.42% |
| 2015 Q3 | 118.63 Million INR | 11.69% |
| 2015 Q1 | 103.04 Million INR | 1650.3% |
| 2015 FY | 362.79 Million INR | 61.0% |
| 2015 Q2 | 106.22 Million INR | 3.09% |
| 2015 Q4 | 102.37 Million INR | -13.71% |
| 2014 Q2 | 106.62 Million INR | 75.97% |
| 2014 Q4 | 5.88 Million INR | -88.73% |
| 2014 Q3 | 52.22 Million INR | -51.02% |
| 2014 Q1 | 60.59 Million INR | 80.84% |
| 2014 FY | 225.33 Million INR | 25.29% |
| 2013 Q3 | 60.27 Million INR | 36.21% |
| 2013 Q1 | 41.81 Million INR | -3.19% |
| 2013 Q2 | 44.25 Million INR | 5.82% |
| 2013 Q4 | 33.5 Million INR | -44.41% |
| 2013 FY | 179.85 Million INR | 22.07% |
| 2012 Q4 | 43.19 Million INR | 70.28% |
| 2012 Q3 | 25.36 Million INR | -54.94% |
| 2012 Q2 | 56.3 Million INR | 150.59% |
| 2012 Q1 | 22.46 Million INR | 227.29% |
| 2012 FY | 147.33 Million INR | 22.42% |
| 2011 Q3 | 24.8 Million INR | 0.0% |
| 2011 FY | 120.34 Million INR | 5.43% |
| 2011 Q4 | 6.86 Million INR | -72.32% |
| 2010 FY | 114.15 Million INR | 5.82% |
| 2009 FY | 107.87 Million INR | 19.03% |
| 2008 FY | 90.62 Million INR | 4.32% |
| 2008 Q4 | 3.92 Million INR | 0.0% |
| 2007 FY | 86.87 Million INR | 0.0% |
| 2007 Q4 | 5.02 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 66.893% |
| Hester Biosciences Limited | 364.77 Million INR | -422.611% |
| Aarti Drugs Limited | 7.14 Billion INR | 73.333% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 39.058% |
| Albert David Limited | 1.33 Billion INR | -42.854% |
| Alembic Limited | 767.77 Million INR | -148.294% |
| Alkem Laboratories Limited | 19.46 Billion INR | 90.205% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -702.121% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -9128.931% |
| Brooks Laboratories Limited | -72.25 Million INR | 2738.443% |
| Eris Lifesciences Limited | 5.18 Billion INR | 63.211% |
| FDC Limited | 3.03 Billion INR | 37.162% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 78.769% |
| Gufic Biosciences Limited | 2.89 Billion INR | 34.124% |
| Hikal Limited | 1.49 Billion INR | -27.582% |
| Ind-Swift Limited | 1.22 Billion INR | -55.496% |
| Innova Captab Limited | 2.53 Billion INR | 24.752% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 61.428% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -790.641% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 63.262% |
| Lupin Limited | 27.75 Billion INR | 93.132% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -6842.705% |
| Medico Remedies Limited | 277.11 Million INR | -587.912% |
| Morepen Laboratories Limited | 4.17 Billion INR | 54.327% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 51.002% |
| Orchid Pharma Limited | 2.36 Billion INR | 19.26% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 31.575% |
| RPG Life Sciences Limited | 2.29 Billion INR | 16.838% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -816.284% |
| Sigachi Industries Limited | 1.47 Billion INR | -29.339% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 149.478% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 58.627% |
| Themis Medicare Limited | 1.3 Billion INR | -46.291% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -30188.02% |
| Wanbury Limited | 1.7 Billion INR | -11.664% |
| Windlas Biotech Limited | 1.29 Billion INR | -46.766% |
| ZIM Laboratories Limited | 1.09 Billion INR | -73.6% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 5.112% |
| Ipca Laboratories Limited | 29.59 Billion INR | 93.559% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.172% |
| Venus Remedies Limited | 534.65 Million INR | -256.556% |
| Sakar Healthcare Limited | 495.5 Million INR | -284.723% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 98.176% |
| Divi's Laboratories Limited | 18.31 Billion INR | 89.589% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 57.39% |
| Mankind Pharma Limited | 40.86 Billion INR | 95.335% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 51.721% |
| Neuland Laboratories Limited | 5.31 Billion INR | 64.154% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 74.723% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 70.683% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 95.8% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -206.964% |
| Wockhardt Limited | 140 Million INR | -1261.663% |
| Bal Pharma Limited | 214.56 Million INR | -788.445% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 97.185% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -54.86% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -245.607% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 73.616% |
| Shilpa Medicare Limited | 3.76 Billion INR | 49.321% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 90.312% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -67241.758% |
| Granules India Limited | 6.52 Billion INR | 70.799% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -664.823% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 92.476% |
| NATCO Pharma Limited | 25.96 Billion INR | 92.657% |
| Suven Life Sciences Limited | -1.22 Billion INR | 255.514% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 63.521% |
| Indoco Remedies Limited | 1.52 Billion INR | -25.054% |
| Alpa Laboratories Limited | 61.51 Million INR | -2998.964% |
| Lasa Supergenerics Limited | -458 Million INR | 516.224% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 146.326% |